The results remained significant when exclusively restricting the set of analysis to the triple positive BC patients, i.e., to patients with a Her2+ disease and with both ER and PR percent cell expression ≥ 50% (p = 0.035). This evidence concerns the gene ERBB2 and breast cancer.